<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Roozekrans, Margot</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">BK Channel Blocker Rapidly Reverses OIRD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">A pharmacokinetic/pharmacodynamic (PK/PD) modeling study on the effect of the BK channel blocker GAL021 found that it produced rapid reversal of opioid-induced respiratory depression (OIRD) in a population of healthy male volunteers. This article discusses a study assessing whether GAL21 stimulates breathing in OIRD and evaluated its safety in a proof-of-concept, double-blind crossover study on isohypercapnic ventilation and a subsequent double-blind exploratory study on poikilocapnic ventilation and nonrespiratory end points.</style></abstract><number><style face="normal" font="default" size="100%">40</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>